FULGENT GENETICS, INC. Accounts Receivable, Allowance for Credit Loss
FULGENT GENETICS, INC. (FLGT) had Accounts Receivable, Allowance for Credit Loss of $25.53 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-07-30
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $25.53M.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $21.42M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $21.41M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $21.53M.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $25.53M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $21.42M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $21.41M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $21.53M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $21.42M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $20.93M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $20.46M 10-K · filed 2026-02-27 |
| 2024-09-30 | $25.32M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $25.31M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $25.83M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $25.23M 10-K · filed 2026-02-27 |
| 2023-09-30 | $29.09M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $33.17M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $38.30M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $41.20M 10-K · filed 2026-02-27 |
| 2022-09-30 | $35.41M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $30.34M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $22.13M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $11.22M 10-K · filed 2025-02-28 |
| 2021-09-30 | $6.89M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $6.04M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $3.85M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $1.90M 10-K · filed 2024-02-28 |
| 2020-09-30 | $1.17M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $864.00K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $862.00K 10-Q · filed 2020-05-06 |
| 2019-12-31 | $751.00K 10-K · filed 2023-02-28 |
| 2019-09-30 | $611.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | $585.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $588.00K 10-Q · filed 2019-05-10 |
| 2018-12-31 | $590.00K 10-K · filed 2022-02-28 |
| 2018-09-30 | $516.00K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $516.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $335.00K 10-Q · filed 2018-05-14 |
| 2017-12-31 | $287.00K 10-K · filed 2020-03-13 |
| 2017-09-30 | $138.00K 10-Q · filed 2017-11-13 |
| 2017-06-30 | $133.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $151.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $151.00K 10-K · filed 2019-03-22 |
| 2016-09-30 | $48.00K 10-Q · filed 2016-11-14 |
| 2015-12-31 | $75.00K 10-K · filed 2018-03-20 |
| 2014-12-31 | $27.00K 10-K · filed 2017-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |